About Ngb Diagnostics Private Limited
Data last updated: 11 February 2026
Ngb Diagnostics Private Limited is a private limited company based in New Delhi, Delhi, India. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 05 June 2012, the company has been in operation for over 14 years.
Registered with ROC Delhi under CIN U74999DL2012PTC236945.
Capital: an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Rakesh Kumar Maurya and Amit Singh Rawat.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.120 3Rd Floor Hargovind Enclave, New Delhi, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.93 Cr, a decline of 33% compared to the previous year.
The company is associated with 1 brand - Ngb Diagnostics.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ngbdx.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No.120 3Rd Floor Hargovind Enclave, New Delhi, Delhi, India – 110092
-
IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited operates one associated brand: NGB Diagnostics. These brands represent Ngb Diagnostics Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers next-generation sequencing and proteomic solutions for diagnostics and research. | ngbdx.com |
Competitors & Alternatives of Ngb Diagnostics Private Limited
Brands and companies operating in the same space as Ngb Diagnostics Private Limited include Abcam, Arbor Biotechnologies, Meridian Bioscience and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Abcam
|
Biological reagents and antibodies are developed for life science research. | Cambridge, United Kingdom, United Kingdom | 1998 |
Arbor Biotechnologies
|
Genomic technologies and drug discovery platforms are provided. | Cambridge, United States, United States | 2016 |
Meridian Bioscience
|
Molecular diagnostic device and kits | Ohio, United States, United States | 1976 |
Singleron
|
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | Hagen, Germany, Germany | 2018 |
Stem Cell Technologies
|
Developer of cell culture media and ancillary reagents for life science research | Vancouver, Canada, Canada | 1993 |
Octant
|
Human cell interaction platform is provided for drug discovery. | Los Angeles, United States, United States | 2017 |
Teknova
|
Molecular biology reagents and kits are supplied for research applications. | Hollister, United States, United States | 1996 |
Business Activity of Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited is engaged in the principal business activity of hospital and medical care, with detailed activities including other hospital and medical care activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities | ********* |
Auditor Details of Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited is audited by N D R & ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| N D R & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited is currently managed by 2 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rakesh Kumar Maurya | Director | 05 Jun 2012 | 14 Years 1 Months | Current |
| Amit Singh Rawat | Director | 18 Aug 2016 | 9 Years 10 Months | Current |
Financials of Ngb Diagnostics Private Limited FY 2025 filings available
Ngb Diagnostics Private Limited reported revenue of ₹1.93 Cr (down 33% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Ngb Diagnostics Private Limited
As of FY 2023, Ngb Diagnostics Private Limited's shareholding pattern shows 99.90% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Ngb Diagnostics Private Limited
View historical data on people associated with Ngb Diagnostics Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Ngb Diagnostics Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Ngb Diagnostics Private Limited
GSTIN & GST Filing Data of Ngb Diagnostics Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Ngb Diagnostics Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Ngb Diagnostics Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Ngb Diagnostics Private Limited
MSME Payment Delays by Ngb Diagnostics Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Ngb Diagnostics Private Limited
Subsidiaries & Group Companies of Ngb Diagnostics Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Ngb Diagnostics Private Limited with ownership details.
MCA Filings & Documents of Ngb Diagnostics Private Limited
MCA Filings & Documents of Ngb Diagnostics Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Ngb Diagnostics Private Limited
Frequently Asked Questions about Ngb Diagnostics Private Limited
Ngb Diagnostics Private Limited is an active private limited company in the healthcare sector based in New Delhi, Delhi, India. It was incorporated on 05 June 2012 (14+ years old) and is registered under CIN U74999DL2012PTC236945.
Ngb Diagnostics Private Limited reported revenue of ₹1.93 Cr for FY 2025 (down 33.00% YoY).
The current directors of Ngb Diagnostics Private Limited are:
The primary industry of Ngb Diagnostics Private Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Ngb Diagnostics Private Limited can be reached at the registered office: Plot No.120 3Rd Floor Hargovind Enclave, New Delhi, Delhi, India – 110092, or through the website ngbdx.com.
The authorised capital is ₹1 Lakh, and the paid-up capital is ₹1 Lakh.